Cabio Biotech Wuhan Co Ltd (688089) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cabio Biotech Wuhan Co Ltd (688089) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥56.10 Million ≈ $8.21 Million USD) by net assets (CN¥1.64 Billion ≈ $239.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cabio Biotech Wuhan Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Cabio Biotech Wuhan Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 688089 liabilities breakdown for a breakdown of total debt and financial obligations.
Cabio Biotech Wuhan Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cabio Biotech Wuhan Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VT Industrial Technology Co Ltd
SHE:300707
|
0.049x |
|
Miwon Specialty Chemical Co Ltd
KO:268280
|
0.059x |
|
Vox Royalty Corp.
TO:VOXR
|
0.024x |
|
Yangzhou Chenhua New Material Co Ltd
SHE:300610
|
-0.012x |
|
IndoStar Capital Finance Limited
NSE:INDOSTAR
|
-0.058x |
|
Cadiz Inc
NASDAQ:CDZI
|
-0.253x |
|
Lootom Telcovideo Network Wuxi Co Ltd
SHE:300555
|
-0.025x |
|
Boss Energy Ltd
AU:BOE
|
0.077x |
Annual Cash Flow Conversion Efficiency for Cabio Biotech Wuhan Co Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Cabio Biotech Wuhan Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Cabio Biotech Wuhan Co Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.57 Billion ≈ $229.67 Million |
CN¥173.04 Million ≈ $25.32 Million |
0.110x | +139.09% |
| 2023-12-31 | CN¥1.49 Billion ≈ $218.60 Million |
CN¥68.89 Million ≈ $10.08 Million |
0.046x | -62.75% |
| 2022-12-31 | CN¥1.43 Billion ≈ $208.53 Million |
CN¥176.40 Million ≈ $25.81 Million |
0.124x | +65.60% |
| 2021-12-31 | CN¥1.38 Billion ≈ $202.20 Million |
CN¥103.29 Million ≈ $15.11 Million |
0.075x | -32.18% |
| 2020-12-31 | CN¥1.32 Billion ≈ $193.67 Million |
CN¥145.88 Million ≈ $21.35 Million |
0.110x | +4.38% |
| 2019-12-31 | CN¥1.25 Billion ≈ $182.85 Million |
CN¥131.95 Million ≈ $19.31 Million |
0.106x | -47.66% |
| 2018-12-31 | CN¥526.20 Million ≈ $77.00 Million |
CN¥106.16 Million ≈ $15.53 Million |
0.202x | -6.93% |
| 2017-12-31 | CN¥464.39 Million ≈ $67.96 Million |
CN¥100.66 Million ≈ $14.73 Million |
0.217x | +39.56% |
| 2016-12-31 | CN¥402.60 Million ≈ $58.91 Million |
CN¥62.53 Million ≈ $9.15 Million |
0.155x | +23.62% |
| 2015-12-31 | CN¥354.83 Million ≈ $51.92 Million |
CN¥44.58 Million ≈ $6.52 Million |
0.126x | +26.32% |
| 2014-12-31 | CN¥465.90 Million ≈ $68.18 Million |
CN¥46.34 Million ≈ $6.78 Million |
0.099x | +7.89% |
| 2013-12-31 | CN¥428.24 Million ≈ $62.66 Million |
CN¥39.48 Million ≈ $5.78 Million |
0.092x | -- |
About Cabio Biotech Wuhan Co Ltd
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.